Scienture Holdings Inc. (SCNX) on Tuesday reported preliminary third-quarter revenue of approximately $1.22 million, up 256% from $344,000 in the previous quarter.

The pharmaceutical company's revenue growth reflected rising sales of its blood pressure medication, Arbli, and initial wholesale shipments of Rezenopy, which launched in August 2026.

New Drug Launch Drives Revenue Growth

Scienture said wholesale unit sales of Arbli increased 74% from the second quarter. Recent additions to institutional drug formularies also supported the product's commercial expansion.

Arbli is an FDA-approved liquid formulation of losartan used to treat high blood pressure and certain related conditions. The formulation offers an alternative for patients who need or prefer liquid medication.

Meanwhile, the August launch of Rezenopy added a second FDA-approved product to Scienture's commercial portfolio.

Rezenopy is a 10-milligram naloxone nasal spray designed for emergency treatment of known or suspected opioid overdoses in adults and children.

Scienture Targets Profitability In 2027

President and Co-CEO Narasimhan Mani said the company expects its expanding product portfolio to support further revenue growth through the remainder of 2026 and into 2027.

He added that Scienture aims to use its historically high gross margins to improve operating leverage as sales increase, supporting its goal of achieving profitability in 2027.

Executive Chairman and Co-CEO Shankar Hariharan highlighted opportunities to expand institutional adoption, strengthen relationships with healthcare providers and pursue commercial partnerships.

The company plans to broaden its distribution network and increase market penetration for both products.

Scienture emphasized that its third-quarter revenue figures remain unaudited and may change following customary adjustments.

The company will report its complete third-quarter financial results in its Form 10-Q filing with the Securities and Exchange Commission.

SCNX Price Action: Scienture Holdings shares were up 2.08% at $3.99 during premarket trading on Tuesday, according to market data.